A children's asthma medication may cause nightmares and other mental health issues, a study claims.
Montelukast, sold in the US as Singulair, is a commonly prescribed asthma medication and one of the 18 best-selling drugs of the 21st century, according to Forbes.
The medication is controversial amid claims that it lacks effectiveness and causes adverse drug reactions, which forced the Food and Drug administration to require for a better label in 2014 that stated the risks.
Experts analyzed the medication and what prevalent symptoms it caused for the user.
They found that montelukast caused an increase in nightmares and mental health issues for children, which they said should be warned by doctors when the medication is prescribed.
Montelukast is a drug used to help with asthma. It has caused problems for patients because of adverse drug reactions people experience. Researchers analyzed the drug and found it was more likely to increase nightmares and depression in children and adults (file photo)
Researchers from the University of Groningen, Netherlands, analyzed the adverse drug reactions of montelukast on adults and children.
This drug is considered a 'blockbuster' medication because it has sold more than $5 billion in medication worldwide every year.
And about nine million people in the United States used the drug from 2012 to 2014.
Reactions towards montelukast were reported to the Netherlands Pharmacovigilance Center Lareb and the World Health Organization's (WHO) Global database.
The researchers found a high amount of patients in the database who reported having allergic granulomatous angiitis, an extremely rare autoimmune disease.
This disease causes inflammation in the small and medium-sized blood vessels in the respiratory system.
It can cause heart disease and kidney damage in its most severe stage.
Eight patients in the Netherlands hospital and 563 people in the WHO database reported having allergic granulomatous angiitis to the drug.
Almost nine million people used montelukast, which is sold in the US as Singulair, from 2012 to 2014 in the United States.
This popular drug has generated more than $5 billion in sales since its